Incidence of Primary Cancers and Intracranial Tumour Recurrences in Growth Hormone-Treated and Untreated Adult Hypopituitary Patients: Analyses from Hypopituitary Control and Complications Study
(2015) In European Journal of Endocrinology 172(6). p.779-790- Abstract
- Speculation remains that growth hormone (GH) treatment is associated with increased neoplasia risk. Studies in GH-treated childhood cancer survivors suggested higher rates of second neoplasms, while cancer risk data for GH-treated and untreated hypopituitary adults have been variable. We present primary cancer risk data from the Hypopituitary Control and Complications Study (HypoCCS) with a focus on specific cancers, and assessment of recurrence rates for pituitary adenoma (PA) and craniopharyngioma (CP).
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/5257637
- author
- Child, Christopher J ; Conroy, Daniel ; Zimmermann, Alan G ; Woodmansee, Whitney ; Erfurth, Eva Marie LU and Robison, Leslie
- organization
- publishing date
- 2015
- type
- Contribution to journal
- publication status
- published
- subject
- in
- European Journal of Endocrinology
- volume
- 172
- issue
- 6
- pages
- 779 - 790
- publisher
- Society of the European Journal of Endocrinology
- external identifiers
-
- pmid:25810462
- wos:000357212600022
- scopus:84930607776
- pmid:25810462
- ISSN
- 1479-683X
- DOI
- 10.1530/EJE-14-1123
- language
- English
- LU publication?
- yes
- id
- 9a2dbbb7-cbd7-41e6-9d27-a9ff106a54bf (old id 5257637)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/25810462?dopt=Abstract
- date added to LUP
- 2016-04-01 10:12:07
- date last changed
- 2024-01-06 10:26:15
@article{9a2dbbb7-cbd7-41e6-9d27-a9ff106a54bf, abstract = {{Speculation remains that growth hormone (GH) treatment is associated with increased neoplasia risk. Studies in GH-treated childhood cancer survivors suggested higher rates of second neoplasms, while cancer risk data for GH-treated and untreated hypopituitary adults have been variable. We present primary cancer risk data from the Hypopituitary Control and Complications Study (HypoCCS) with a focus on specific cancers, and assessment of recurrence rates for pituitary adenoma (PA) and craniopharyngioma (CP).}}, author = {{Child, Christopher J and Conroy, Daniel and Zimmermann, Alan G and Woodmansee, Whitney and Erfurth, Eva Marie and Robison, Leslie}}, issn = {{1479-683X}}, language = {{eng}}, number = {{6}}, pages = {{779--790}}, publisher = {{Society of the European Journal of Endocrinology}}, series = {{European Journal of Endocrinology}}, title = {{Incidence of Primary Cancers and Intracranial Tumour Recurrences in Growth Hormone-Treated and Untreated Adult Hypopituitary Patients: Analyses from Hypopituitary Control and Complications Study}}, url = {{http://dx.doi.org/10.1530/EJE-14-1123}}, doi = {{10.1530/EJE-14-1123}}, volume = {{172}}, year = {{2015}}, }